Loading
X-Chem, Inc.
X-Chem, Inc. is a biotechnology company based in Waltham, Massachusetts, focused on small molecule drug discovery using DNA-Encoded Library (DEL) technology, medicinal chemistry, and artificial intelligence. Founded in 2010, X-Chem partners with pharmaceutical and biotech firms to provide comprehensive solutions for complex therapeutic targets. The company offers services such as DEL screening, hit-to-lead optimization, lead optimization, and candidate identification. X-Chem utilizes a proprietary DEL platform with over 200 billion small molecules, allowing for the simultaneous screening of billions of compounds against specific biological targets. Its ArtemisAI platform combines AI with DEL data to enhance the drug discovery process. X-Chem has a strong track record, achieving an approximately 80% success rate in identifying functional hits and licensing around 100 research programs. The company has delivered four clinical candidates since 2021 and has validated its technologies across approximately 30 challenging target classes. With a workforce of 201–500 employees, X-Chem also has global locations in Montreal, Budapest, and previously London.
Funding
Every round, secondary, debt facility or acquisition involving X-Chem, Inc. that Lounge tracks, newest first.
No rounds recorded yet.
Paid members see the full deals desk — every AI round and exit, filterable by type, sector and country, with investors and reported ARR, plus CSV exports. Developer membership is $9/mo.
See plans →Log inKey numbers
—
0
—
$40M